Chief Business Officer, evitria AG | Biotechnology and Cell Culture Expert | Advocate for Sustainability | Leading the Future in the Production of Antibodies
Scaling always comes with challenges, but the challenges many organisations face when scaling antibody production are unique. For organisations that are conducting multiple trials, figuring out the right formulations for each candidate can be incredibly resource-intensive. Ultimately, this extends development timelines and can be unviable for smaller companies. evitria's manufacturing services cut this out. By delivering molecules to our clients in just a few weeks, we help them to scale their drug development capabilities and enable them to focus their efforts on the work that matters most: testing. Learn more about what we do in this episode of the UNCAGED Show: https://lnkd.in/eA2QEWmK #TheUNCAGEDShow #BispecificAntibodies #Antibodies
